Guidelines from organizations like the WHO and NCCN recommend COX-2 inhibitors for cancer patients with liver or kidney metastases, as they may reduce the gastrointestinal side effects and renal toxicity associated with traditional NSAIDs [15, 17]. Here, PTGS2 is linked to cancer.